Updated
Genmab ASGMAB · Healthcare
$53.63+1.69%
Market cap$32.9B
IndustryBiotechnology
Genmab AS (GMAB) Superinvestor holders
10 of the superinvestors we track hold Genmab AS (GMAB) in their latest 13F filings, $458M in total.
Summary
The largest holder is Arrowstreet Capital, with $137M, 0.1% of the portfolio.
In their latest quarter: 2 opened a new position, 4 added, 3 trimmed.
Who holds it
Each investor's latest 13F filing, largest stake first. What a 13F shows.
| Investor | Last change | Shares | Value | % of portfolio | Filed for |
|---|---|---|---|---|---|
| Arrowstreet Capital | Held | 4,975,324 | $137M | 0.1% | Q2 2026 |
| Jim Simons Renaissance Technologies |
Trimmed | 3,517,850 | $97M | 0.1% | Q2 2026 |
| Two Sigma Two Sigma Investments |
Added | 3,506,843 | $96M | 0.1% | Q2 2026 |
| Harding Loevner | Trimmed | 3,086,318 | $87M | 0.8% | Q2 2026 |
| Paul Marshall Marshall Wace |
Added | 829,659 | $23M | 0.0% | Q2 2026 |
| Louis Bacon Moore Capital Management |
Added | 420,487 | $12M | 0.3% | Q2 2026 |
| Steve Cohen Point72 Asset Management |
New position | 135,647 | $4M | 0.0% | Q2 2026 |
| Cliff Asness AQR Capital Management |
Added | 106,104 | $3M | 0.0% | Q2 2026 |
| Ken Tropin Graham Capital Management |
New position | 20,343 | $558,822 | 0.0% | Q2 2026 |
| Fred DiSanto Ancora Holdings |
Trimmed | 43 | $1,181 | 0.0% | Q2 2026 |
Holders by quarter
| Quarter | Superinvestors holding it |
|---|---|
| Q2 2026 | 10 |
| Q1 2026 | 8 |
| Q4 2025 | 10 |
| Q3 2025 | 9 |
| Q2 2025 | 9 |
| Q1 2025 | 10 |
| Q4 2024 | 11 |
| Q3 2024 | 10 |
Questions about Genmab AS
Which superinvestors own Genmab AS?
10 of the superinvestors we track hold Genmab AS (GMAB) in their latest 13F filings, $458M in total. Arrowstreet Capital, Jim Simons, Two Sigma, Harding Loevner, Paul Marshall, Louis Bacon.
Who is the largest superinvestor holder of GMAB?
The largest holder is Arrowstreet Capital, with $137M, 0.1% of the portfolio.
From Genmab AS's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.